Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination

Exclusion Criteria

• •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• •Planned administration/administration of a vaccine not foreseen by the study protocol during the study period starting from 30 days before each dose and ending 30 days after each dose of vaccine(s).
• •Previous vaccination against S. pneumoniae since birth.
• •History of any hypersensitivity reaction following any previous vaccination.
• •Eczema and any history of allergy
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required), including human immunodeficiency virus infection.
• •A family history of congenital or hereditary immunodeficiency.
• •Major congenital defects or any chronic illness.
• •History of any neurologic disorders or seizures.
• •Acute disease and/or fever at the time of enrolment.
• •Fever is defined as temperature \>= 37.5°C on oral or axillary setting, or \>= 38.0°C on rectal setting.
• •Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
• •Administration of immunoglobulins and/ or any blood products within the 3 months preceding the first dose of study vaccine or planned use during the study period.
• •Child in care.